Abstract
The essential oils of Cymbopogon citratus (EOCC) has found use in medicine, food and chemical industry. This study attempts to provide evidence of its suitability for antioxidant and anti-inflammatory therapy. Total phenol and total flavonoid of EOCC was 49.83±0.39mg GAE/g of extract and 352.82±3.45 µg QEC/g of extract respectively. Gas chromatography-mass spectrometry (GC-MS) analysis of its essential oil (EOCC) showed 25 peaks with myrcenyl acetate (9.703%), caryophyllene (8.997%), citronella (6.383%) been the most abundant. The in vitro anti-inflammatory assay using human red blood cell (HRBC) membrane stabilization shows that at 200µg/mL, the percentage inhibition of EOCC was significantly higher compared to diclofenac both for heat-induced and hypotonic induced haemolysis. 2,2-diphenyl-1-picrylhydrazyl (DPPH) and ferric reducing antioxidant power (FRAP) assays showed a comparable and dose-dependent increase from 50 to 400 μg/mL in relation to vitamin C. Half maximal inhibitory concentration (IC50) of EOCC (73.16±12.89 μg/mL and 656.01±0.01 μmol Fe (II)/L) was remarkably higher compared to that of vitamin C (69.09±4.52 μg/mL and 246.79±0.01 μmol Fe (II)/L) both for DPPH and FRAP assays respectively. In conclusion, results from this study establish preliminary evidence on the therapeutic potential of EOCC in managing inflammation and oxidative stress caused by free radicals.
Anti-inflammatory activity of Cymbopogon citratus leaves infusion via proteasome and nuclear factor-κB pathway inhibition: Contribution of chlorogenic acid
